Transcend Therapeutics
A founding funder of the Johns Hopkins Center for Psychedelic & Consciousness Research, Craig has been dedicated to supporting the reemergence of psychedelic therapies. From 2005-2018, he managed Brenner West Capital Partners, a hedge fund with over $1.5 billion in assets under management. He is the Chairman of Reconsider, Integrated's affiliated non-profit entity and serves on the board of SkyKick, a software company automating IT workflows in the cloud. He previously served on the board of Bowery Residents’ Committee, New York City’s leading homeless services organization and was chairman of Village Health Works, a community-based health center in Burundi, Africa.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Transcend Therapeutics
1 followers
Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications.